Azevan Pharmaceuticals, Inc. (www.azevan.com), which is developing novel small molecule medicines for disorders of stress, mood, and behavior, announced that enrollment has been completed in a Phase 2 clinical study of the company’s lead compound SRX246 in adults with DSM-5 Intermittent Explosive Disorder. Read more: http://prn.to/1X1HV2d
Client & Alumni News
Azevan Pharmaceuticals Advances Study of Drug for Intermittent Explosive Disorder
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.